Researchers from Northeastern University in the US confirmed that one of those genes plays a causal role in cardiac hypertrophy - abnormal thickening of the heart muscle - which can lead to heart failure.
"This is an exciting direction for personalised medicine, and also for identifying genes and therapeutic targets for complex diseases that involve many genes," said Alain Karma from Northeastern.
The ultimate goal is to create personalised therapeutic drugs to reverse heart disease.
"The method can predict beforehand whether a patient should be prescribed a different drug using just a simple blood test. This would save time and accelerate the therapy," Santolini said.
In the traditional approach to find genes related to heart disease, researchers take donated hearts from people who died unexpectedly but were previously healthy.
They analyse the gene expression - the amount of messenger RNA and proteins - produced by the genes of healthy hearts and compare it with the gene expression of sick hearts explanted from end-stage heart failure patients undergoing heart transplant.
His team took a different approach - using the Hybrid Mouse Diversity Panel, a collection of 100 genetically different strains of mice that can be used to analyse the genetic and environmental factors underlying complex traits.
Within each strain, the mice are inbred, making them all identical twins on a genetic level.
Researchers took two mice from the same strain and gave one of them a stressor drug that induces heart failure.
They then compared the stressed mouse's gene expression with its non-stressed twin. Since the mice have the same genome, they were able to pinpoint individual genes that changed expression as a direct result of the heart stressor. The researchers identified 36 such genes.
The researchers confirmed the gene's role by using molecular biology techniques to silence it and observe the resulting changes of expression.
They found the transcription factor gene was directly connected to a whole network of proteins known to play a role in cardiac hypertrophy.
One of the genes Karma found, called RFFL, was previously known to researchers to be implicated in other cardiac processes. However, it was not known to be related to hypertrophy.
"When you are comparing two populations of cells from the same person - one that has been controlled and one that has been under the effect of a drug or stressor - you can compare the change of gene expression in a personalised way," Karma said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
